Mylan announced the launch of Dextroamphetamine Sulfate Extended-Release Capsules, the generic version of Amedra‘s Dexedrine.  

Dexedrine, a CII substance, is indicated for narcolepsy and attention deficit disorder with hyperactivity as part of a total treatment program that includes psychological, educational, social measures for patients aged 6–16 years. It is a noncatecholamine, sympathomimetic amine with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

Dextroamphetamine Sulfate Extended-Release Capsules are available as 5mg, 10mg, and 15mg strengths.

For more information call (800) RX-MYLAN or visit Mylan.com.